Local treatment with BPPcysMPEG reduces allergic airway inflammation in sensitized mice

Immunobiology

Volumn 216, Issue 1-2, 2011, Pages 110-117

  Knothe, S ^a   Mutschler, V ^a   Rochlitzer, S ^a   Winkler, C ^a   Ebensen, T ^b   Guzman, C A ^b   Hohlfeld, J ^a   Braun, A ^a   Muller, M ^a  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Allergic airway inflammation; BPPcysMPEG; Immunomodulation; Th1; TLR2 6 agonist

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; INTERLEUKIN 4; INTERLEUKIN 5; PEGYLATED BISACYLOXYPROPYLCYSTEINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL COMPOSITION; CELL STIMULATION; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INNATE IMMUNITY; LUNG LAVAGE; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MALE; MEDIASTINUM LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION; SPLEEN CELL; TH2 CELL;

ALLERGENS; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; RECEPTOR CROSS-TALK; RESPIRATORY HYPERSENSITIVITY; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6;

EID: 78649513070     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.05.003     Document Type: Article

References (35)

1. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
2. Akdis C.A. Allergy and hypersensitivity: mechanisms of allergic disease. Curr. Opin. Immunol. 2006, 18:718-726.
3. Akdis C.A., Blaser K., Akdis M. Apoptosis in tissue inflammation and allergic disease. Curr. Opin. Immunol. 2004, 16:717-723.
4. Akdis M., Akdis C.A. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 2007, 119:780-791.
5. Akdis M., Akdis C.A. Therapeutic manipulation of immune tolerance in allergic disease. Nat. Rev. Drug Discov. 2009, 8:645-660.
6. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 2002, 347:911-920.
7. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004, 430:257-263.
8. Borsutzky S., Ebensen T., Link C., Becker P.D., Fiorelli V., Cafaro A., Ensoli B., Guzman C.A. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 2006, 24:2049-2056.
9. Brusselle G.G., Kips J.C., Tavernier J.H., van der Heyden J.G., Cuvelier C.A., Pauwels R.A., Bluethmann H. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin. Exp. Allergy 1994, 24:73-80.
10. Cohn L., Tepper J.S., Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J. Immunol. 1998, 161:3813-3816.
11. Drachenberg K.J., Wheeler A.W., Stuebner P., Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56:498-505.
12. Ebner C., Siemann U., Bohle B., Willheim M., Wiedermann U., Schenk S., Klotz F., Ebner H., Kraft D., Scheiner O. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 1997, 27:1007-1015.
13. Eder W., Klimecki W., Yu L., von Mutius E., Riedler J., Braun-Fahrlander C., Nowak D., Martinez F.D. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J. Allergy Clin. Immunol. 2004, 113:482-488.
14. Fuchs B., Knothe S., Rochlitzer S., Nassimi M., Greweling M., Lauenstein H.D., Nassenstein C., Muller M., Ebensen T., Dittrich A.M., Krug N., Guzman C.A., Braun A. A Toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitisation to timothy grass pollen antigens. Int. Arch. Allergy Immunol. 2009, 152:131-139.
15. Gavett S.H., Chen X., Finkelman F., Wills-Karp M. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am. J. Respir. Cell Mol. Biol. 1994, 10:587-593.
16. Kildsgaard J., Brimnes J., Jacobi H., Lund K. Sublingual immunotherapy in sensitized mice. Ann. Allergy Asthma Immunol. 2007, 98:366-372.
17. Lombardi V., Van Overtvelt L., Horiot S., Moussu H., Chabre H., Louise A., Balazuc A.M., Mascarell L., Moingeon P. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin. Exp. Allergy 2008, 38:1819-1829.
18. Niebuhr M., Muhlradt P.F., Wittmann M., Kapp A., Werfel T. Intracutaneous injection of the macrophage-activating lipopeptide-2 (MALP-2) which accelerates wound healing in mice - a phase I trial in 12 patients. Exp. Dermatol. 2008, 17:1052-1056.
19. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8:275-283.
20. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., Schroeder L., Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:13766-13771.
21. Page K., Ledford J.R., Zhou P., Wills-Karp M. A TLR2 agonist in German cockroach frass activates MMP-9 release and is protective against allergic inflammation in mice. J. Immunol. 2009, 183:3400-3408.
22. Patel M., Xu D., Kewin P., Choo-Kang B., McSharry C., Thomson N.C., Liew F.Y. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J. Immunol. 2005, 174:7558-7563.
23. Raby B.A., Klimecki W.T., Laprise C., Renaud Y., Faith J., Lemire M., Greenwood C., Weiland K.M., Lange C., Palmer L.J., Lazarus R., Vercelli D., Kwiatkowski D.J., Silverman E.K., Martinez F.D., Hudson T.J., Weiss S.T. Polymorphisms in toll-like receptor 4 are not associated with asthma or atopy-related phenotypes. Am. J. Respir. Crit. Care Med. 2002, 166:1449-1456.
24. Reppe K., Tschernig T., Luhrmann A., van L.V., Grote K., Zemlin M.V., Gutbier B., Muller H.C., Kursar M., Schutte H., Rosseau S., Pabst R., Suttorp N., Witzenrath M. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. Am. J. Respir. Cell Mol. Biol. 2009, 40:474-481.
25. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J. Allergy Clin. Immunol. 2004, 113:395-400.
26. Schneider C., Schmidt T., Ziske C., Tiemann K., Lee K.M., Uhlinsky V., Behrens P., Sauerbruch T., Schmidt-Wolf I.G., Muhlradt P.F., Schmidt J., Marten A. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004, 53:355-361.
27. Secrist H., Chelen C.J., Wen Y., Marshall J.D., Umetsu D.T. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med. 1993, 178:2123-2130.
28. Sel S., Wegmann M., Sel S., Bauer S., Garn H., Alber G., Renz H. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J. Immunol. 2007, 178:7805-7813.
29. Takeuchi O., Kawai T., Muhlradt P.F., Morr M., Radolf J.D., Zychlinsky A., Takeda K., Akira S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 2001, 13:933-940.
30. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., Modlin R.L., Akira S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 2002, 169:10-14.
31. Weigt H., Muhlradt P.F., Emmendorffer A., Krug N., Braun A. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology 2003, 207:223-233.
32. Weigt H., Muhlradt P.F., Larbig M., Krug N., Braun A. The Toll-like receptor-2/6 agonist macrophage-activating lipopeptide-2 cooperates with IFN-gamma to reverse the Th2 skew in an in vitro allergy model. J. Immunol. 2004, 172:6080-6086.
33. Weigt H., Nassenstein C., Tschernig T., Muhlradt P.F., Krug N., Braun A. Efficacy of macrophage-activating lipopeptide-2 combined with interferon-gamma in a murine asthma model. Am. J. Respir. Crit. Care Med. 2005, 172:566-572.
34. West A.P., Koblansky A.A., Ghosh S. Recognition and signaling by toll-like receptors. Annu. Rev. Cell Dev. Biol. 2006, 22:409-437.
35. Zhao Y., Yang J., Gao Y.D., Guo W. Th17 immunity in patients with allergic asthma. Int. Arch. Allergy Immunol. 2009, 151:297-307.